April 21, 2018 10:44 PM ET


Company Overview of Vaxil Bio Ltd.

Company Overview

Vaxil Bio Ltd., an immuno-oncology biotechnology company, engages in the development of novel immunotherapies for the treatment of cancer and infectious diseases in Israel. Its immunotherapies include neoantigen-like peptides, as well as antibodies. The company’s lead product is ImMucin, which completed a Phase I/II clinical trial for the treatment of multiple myeloma cancer; and is in Phase I/II clinical trials for the treatment of metastatic breast cancer patients in combination with hormonal therapy. It also develops SPmAb-2.1 and SPmAb-6, which are antibodies for the diagnosis and treatment of cancer; and MTbuVax, a multi-antigenic and multi-epitope subunit vaccine, which is in pre-clini...

4576 Yonge Street

6th Floor

Toronto, ON M2N 6N4


Founded in 2006

Key Executives for Vaxil Bio Ltd.

CFO & Director
Age: 44
Total Annual Compensation: C$49.5K
Compensation as of Fiscal Year 2016.

Vaxil Bio Ltd. Key Developments

Vaxil Bio Ltd. To Be Deleted From Other OTC

Vaxil Bio Ltd.'s Ordinary Shares (Israel) will be deleted from Other OTC effective March 12, 2018. The deletion was due to Inactive Security.

Vaxil Bio Ltd. Announces Board Changes

Vaxil Bio Ltd. announced that Dr. Saeid Babaei has resigned from his role as Chairman of the Board of Directors. Mr. Isaac Maresky has accepted the role of Chairman for the time being.

Vaxil Bio Ltd. Announces Management Changes

VAXIL BIO LTD. announced the addition of two veteran healthcare executives to its Board of Directors. Dr. Ari Kellen, formerly of McKinsey & Company, Bausch + Lomb, and Valeant; together with Dr. Shawn Langer, formerly of McKinsey & Company, and a current healthcare private equity portfolio manager with BMHS Investments, have joined Vaxil's Board of Directors. Director Mr. Isaac Maresky, an investment banking professional with hundreds of millions of dollars of financings and M&A experience, including co-founding another successful immunotherapy company, has been appointed CEO of Vaxil. The new appointments will bring Vaxil's Board of Directors to five members, namely Dr. Saeid Babaei, Dr. Ari Kellen, Dr. Shawn Langer, Mr. Isaac Maresky, and Mr. Gadi Levin. Vaxil thanks Drs. Benjamin Chen and Limor Chen, who have resigned their positions, for their service to the Company.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

Private Placement
December 5, 2017

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States
NYC2012, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Vaxil Bio Ltd., please visit www.vxlbio.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.